{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:17:08Z","timestamp":1790385428577,"version":"4.1.0"},"reference-count":239,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,21]],"date-time":"2015-08-21T00:00:00Z","timestamp":1440115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/igo\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["2011 53 05"],"award-info":[{"award-number":["2011 53 05"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["2010 53 04"],"award-info":[{"award-number":["2010 53 04"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["2007IARC01"],"award-info":[{"award-number":["2007IARC01"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the International Agency for Research on Cancer"}],"content-domain":{"domain":["cancerepidemiology.net","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Epidemiology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.canep.2015.08.003","type":"journal-article","created":{"date-parts":[[2015,9,26]],"date-time":"2015-09-26T17:45:37Z","timestamp":1443289537000},"page":"S107-S119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"S1","title":["European Code against Cancer 4th Edition: Medical exposures, including hormone therapy, and cancer"],"prefix":"10.1016","volume":"39","author":[{"given":"S\u00f8ren","family":"Friis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ausrele","family":"Kesminiene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Espina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anssi","family":"Auvinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Straif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Sch\u00fcz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canep.2015.08.003_bib0005","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.canep.2015.05.009","article-title":"European Code against Cancer 4th Edition: 12 ways to reduce your cancer risk","volume":"39","author":"Sch\u00fcz","year":"2015","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.canep.2015.08.003_bib0010","article-title":"IARC monographs on the evaluation of carcinogenic risks to humans","volume":"vol. 91","author":"International Agency for Research on Cancer","year":"2007"},{"key":"10.1016\/j.canep.2015.08.003_bib0015","article-title":"IARC monographs on the evaluation of carcinogenic risks to humans","volume":"vol. 100A","author":"International Agency for Research on Cancer","year":"2012"},{"issue":"3","key":"10.1016\/j.canep.2015.08.003_bib0020","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s11912-013-0303-y","article-title":"Benefit and harms of new anti-cancer drugs","volume":"15","author":"Vera-Badillo","year":"2013","journal-title":"Curr. Oncol. Rep."},{"issue":"2","key":"10.1016\/j.canep.2015.08.003_bib0025","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1093\/toxsci\/kfh167","article-title":"Human carcinogenic risk evaluation, Part III. Assessing cancer hazard and risk in human drug development","volume":"81","author":"Jacobs","year":"2004","journal-title":"Toxicol. Sci."},{"issue":"21","key":"10.1016\/j.canep.2015.08.003_bib0030","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1001\/archinte.164.21.2308","article-title":"Hormone therapy: making decisions in the face of uncertainty","volume":"164","author":"Peterson","year":"2004","journal-title":"Arch. Intern. Med."},{"issue":"23","key":"10.1016\/j.canep.2015.08.003_bib0035","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1200\/JCO.2009.26.3756","article-title":"American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer","volume":"28","author":"Burstein","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.canep.2015.08.003_bib0040","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.canep.2015.08.003_bib0045","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrc3397","article-title":"Future directions in cancer prevention","volume":"12","author":"Umar","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"Suppl. (1)","key":"10.1016\/j.canep.2015.08.003_bib0050","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00280-003-0596-x","article-title":"Strategy for the development of novel anticancer drugs","volume":"52","author":"Saijo","year":"2003","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"12","key":"10.1016\/j.canep.2015.08.003_bib0055","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1158\/1078-0432.CCR-06-1104","article-title":"Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer\u2014a plan to move forward","volume":"12","author":"Kelloff","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canep.2015.08.003_bib0060","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/j.canep.2015.03.016","article-title":"European Code against Cancer 4th Edition: ionising and non-ionising radiation and cancer","volume":"39","author":"McColl","year":"2015","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.canep.2015.08.003_bib0065","series-title":"Making the Best Use of a Department of Clinical Radiology","author":"Royal College of Radiologists","year":"1998"},{"issue":"24","key":"10.1016\/j.canep.2015.08.003_bib0070","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1093\/jnci\/djr483","article-title":"Preventable exposures associated with human cancers","volume":"103","author":"Cogliano","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canep.2015.08.003_bib0075","series-title":"Current Management of the Menopause","author":"Lauritzen","year":"2005"},{"issue":"Suppl. (12B)","key":"10.1016\/j.canep.2015.08.003_bib0080","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.amjmed.2005.09.059","article-title":"Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration","volume":"118","author":"Stefanick","year":"2005","journal-title":"Am. J. Med."},{"key":"10.1016\/j.canep.2015.08.003_bib0085","series-title":"The Complete Drug Reference","author":"Martindale","year":"2014"},{"issue":"6152","key":"10.1016\/j.canep.2015.08.003_bib0090","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1136\/bmj.2.6152.1643-c","article-title":"Progestogen modification of endometrial histology in menopasual women","volume":"2","author":"Whitehead","year":"1978","journal-title":"Br. Med. J."},{"issue":"9084","key":"10.1016\/j.canep.2015.08.003_bib0095","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0140-6736(97)08233-0","article-title":"Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer","volume":"350","author":"Collaborative Group on Hormonal Factors in Breast Cancer","year":"1997","journal-title":"Lancet"},{"issue":"3 Pt. 2","key":"10.1016\/j.canep.2015.08.003_bib0100","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/0002-9378(95)90247-3","article-title":"Benefits and risks of estrogen replacement therapy","volume":"173","author":"Lobo","year":"1995","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.canep.2015.08.003_bib0105","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.canep.2015.08.003_bib0110","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa030808","article-title":"Estrogen plus progestin and the risk of coronary heart disease","volume":"349","author":"Manson","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.canep.2015.08.003_bib0115","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11883-002-0062-y","article-title":"Postmenopausal hormone replacement therapy as antiatherosclerotic therapy","volume":"4","author":"Hodis","year":"2002","journal-title":"Curr. Atheroscler Rep."},{"issue":"14","key":"10.1016\/j.canep.2015.08.003_bib0120","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"},{"issue":"16","key":"10.1016\/j.canep.2015.08.003_bib0125","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJMsr070105","article-title":"The decrease in breast cancer incidence in 2003 in the United States","volume":"356","author":"Ravdin","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.canep.2015.08.003_bib0130","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10549-007-9566-z","article-title":"Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy","volume":"107","author":"Katalinic","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.canep.2015.08.003_bib0135","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1471-2407-6-78","article-title":"Remarkable change in age-specific breast cancer incidence in the Swiss canton of Geneva and its possible relation with the use of hormone replacement therapy","volume":"6","author":"Bouchardy","year":"2006","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.canep.2015.08.003_bib0140","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1056\/NEJMoa0807684","article-title":"Breast cancer after use of estrogen plus progestin in postmenopausal women","volume":"360","author":"Chlebowski","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.canep.2015.08.003_bib0145","doi-asserted-by":"crossref","first-page":"R4","DOI":"10.1186\/bcr2467","article-title":"Recent breast cancer incidence trends according to hormone therapy use: the California Teachers Study cohort","volume":"12","author":"Marshall","year":"2010","journal-title":"Breast Cancer Res."},{"issue":"1","key":"10.1016\/j.canep.2015.08.003_bib0150","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/bcr2463","article-title":"Recent declines in breast cancer incidence: mounting evidence that reduced use of menopausal hormones is largely responsible","volume":"12","author":"Banks","year":"2010","journal-title":"Breast Cancer Res."},{"issue":"2","key":"10.1016\/j.canep.2015.08.003_bib0155","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3109\/13697137.2013.829812","article-title":"Systematic review about breast cancer incidence in relation to hormone replacement therapy use","volume":"17","author":"Antoine","year":"2014","journal-title":"Climacteric"},{"issue":"3","key":"10.1016\/j.canep.2015.08.003_bib0160","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.maturitas.2008.10.009","article-title":"The EMAS 2008 update on clinical recommendations on postmenopausal hormone replacement therapy","volume":"61","author":"Gompel","year":"2008","journal-title":"Maturitas"},{"issue":"3","key":"10.1016\/j.canep.2015.08.003_bib0165","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3109\/13697137.2011.570590","article-title":"Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health","volume":"14","author":"Sturdee","year":"2011","journal-title":"Climacteric"},{"issue":"2","key":"10.1016\/j.canep.2015.08.003_bib0170","doi-asserted-by":"crossref","first-page":"104","DOI":"10.7326\/0003-4819-157-2-201207170-00466","article-title":"Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the U.S. Preventive Services Task Force recommendations","volume":"157","author":"Nelson","year":"2012","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.canep.2015.08.003_bib0175","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7326\/0003-4819-158-1-201301010-00553","article-title":"Menopausal hormone therapy for the primary prevention of chronic conditions: U.S. Preventive Services Task Force recommendation statement","volume":"158","author":"Moyer","year":"2013","journal-title":"Ann. Intern. Med."},{"issue":"13","key":"10.1016\/j.canep.2015.08.003_bib0180","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1001\/jama.2011.382","article-title":"Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial","volume":"305","author":"Lacroix","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.canep.2015.08.003_bib0185","doi-asserted-by":"crossref","first-page":"e6409","DOI":"10.1136\/bmj.e6409","article-title":"Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial","volume":"345","author":"Schierbeck","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.canep.2015.08.003_bib0190","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002229.pub4","article-title":"Hormone therapy for preventing cardiovascular disease in post-menopausal women","volume":"3","author":"Boardman","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"issue":"9382","key":"10.1016\/j.canep.2015.08.003_bib0195","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(03)14065-2","article-title":"Breast cancer and hormone-replacement therapy in the Million Women Study","volume":"362","author":"Beral","year":"2003","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.canep.2015.08.003_bib0200","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/humupd\/dmi028","article-title":"Breast cancer risk with postmenopausal hormonal treatment","volume":"11","author":"Collins","year":"2005","journal-title":"Hum. Reprod. Update"},{"issue":"6","key":"10.1016\/j.canep.2015.08.003_bib0205","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/humupd\/dmi031","article-title":"Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials","volume":"11","author":"Greiser","year":"2005","journal-title":"Hum. Reprod. Update"},{"issue":"1","key":"10.1016\/j.canep.2015.08.003_bib0210","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ijc.25314","article-title":"Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition","volume":"128","author":"Bakken","year":"2011","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.canep.2015.08.003_bib0215","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/jnci\/djq527","article-title":"Breast cancer risk in relation to the interval between menopause and starting hormone therapy","volume":"103","author":"Beral","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"issue":"8","key":"10.1016\/j.canep.2015.08.003_bib0220","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/jnci\/djt043","article-title":"Estrogen plus progestin and breast cancer incidence and mortality in the Women\u2019s Health Initiative Observational Study","volume":"105","author":"Chlebowski","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.canep.2015.08.003_bib0225","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S1470-2045(12)70075-X","article-title":"Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women\u2019s Health Initiative randomised placebo-controlled trial","volume":"13","author":"Anderson","year":"2012","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.canep.2015.08.003_bib0230","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/aje\/kwn090","article-title":"Conjugated equine estrogens and breast cancer risk in the Women\u2019s Health Initiative clinical trial and observational study","volume":"167","author":"Prentice","year":"2008","journal-title":"Am. J. Epidemiol."},{"issue":"2","key":"10.1016\/j.canep.2015.08.003_bib0235","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/2042098614568300","article-title":"Menopausal hormone therapy and breast cancer mortality: clinical implications","volume":"6","author":"Chlebowski","year":"2015","journal-title":"Ther. Adv. Drug Saf."},{"issue":"5","key":"10.1016\/j.canep.2015.08.003_bib0240","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S1470-2045(12)70075-X","article-title":"Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women\u2019s Health Initiative randomised placebo-controlled trial","volume":"13","author":"Anderson","year":"2012","journal-title":"Lancet Oncol."},{"issue":"31","key":"10.1016\/j.canep.2015.08.003_bib0245","doi-asserted-by":"crossref","first-page":"5138","DOI":"10.1200\/JCO.2008.21.6432","article-title":"Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?","volume":"27","author":"Fournier","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.canep.2015.08.003_bib0250","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/S1470-2045(06)70911-1","article-title":"Hormonal therapy for menopause and breast cancer risk by histological type: a cohort study and meta-analysis","volume":"7","author":"Reeves","year":"2006","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.canep.2015.08.003_bib0255","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1093\/aje\/kwn044","article-title":"Estrogen plus progestin therapy and breast cancer in recently postmenopausal women","volume":"167","author":"Prentice","year":"2008","journal-title":"Am. J. Epidemiol."},{"issue":"1","key":"10.1016\/j.canep.2015.08.003_bib0260","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10549-011-1848-9","article-title":"Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone women\u2019s health initiative clinical trials","volume":"132","author":"Crandall","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"issue":"18","key":"10.1016\/j.canep.2015.08.003_bib0265","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/jnci\/djt207","article-title":"Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density","volume":"105","author":"Hou","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"issue":"11","key":"10.1016\/j.canep.2015.08.003_bib0270","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nrclinonc.2011.110","article-title":"Hormone replacement therapy and the risk of breast cancer","volume":"8","author":"Narod","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canep.2015.08.003_bib0275","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jsbmb.2013.06.010","article-title":"Menopausal hormone therapy and breast cancer","volume":"142","author":"Santen","year":"2014","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"4","key":"10.1016\/j.canep.2015.08.003_bib0280","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/jnci\/djq561","article-title":"The influence of time from menopause and mammography on hormone therapy-related breast cancer risk assessment","volume":"103","author":"Chlebowski","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"issue":"3","key":"10.1016\/j.canep.2015.08.003_bib0285","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/ijc.20710","article-title":"Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort","volume":"114","author":"Fournier","year":"2005","journal-title":"Int. J. Cancer"},{"issue":"7","key":"10.1016\/j.canep.2015.08.003_bib0290","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/sj.bjc.6602472","article-title":"Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study","volume":"92","author":"Ewertz","year":"2005","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.canep.2015.08.003_bib0295","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s10654-005-0032-0","article-title":"Factors modifying the association between hormone-replacement therapy and breast cancer risk","volume":"20","author":"Pesch","year":"2005","journal-title":"Eur. J. Epidemiol."},{"issue":"15","key":"10.1016\/j.canep.2015.08.003_bib0300","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/jama.2010.1500","article-title":"Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women","volume":"304","author":"Chlebowski","year":"2010","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.canep.2015.08.003_bib0305","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s10552-011-9782-z","article-title":"Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition","volume":"22","author":"Tsilidis","year":"2011","journal-title":"Cancer Causes Control"},{"issue":"13","key":"10.1016\/j.canep.2015.08.003_bib0310","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2013.278040","article-title":"Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women\u2019s Health Initiative randomized trials","volume":"310","author":"Manson","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.canep.2015.08.003_bib0315","first-page":"CD000402","article-title":"Hormone therapy in postmenopausal women and risk of endometrial hyperplasia","volume":"8","author":"Furness","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.canep.2015.08.003_bib0320","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/0029-7844(94)00383-O","article-title":"Hormone replacement therapy and endometrial cancer risk: a meta-analysis","volume":"85","author":"Grady","year":"1995","journal-title":"Obstet. Gynecol."},{"issue":"9470","key":"10.1016\/j.canep.2015.08.003_bib0325","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(05)66455-0","article-title":"Endometrial cancer and hormone-replacement therapy in the Million Women Study","volume":"365","author":"Beral","year":"2005","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.canep.2015.08.003_bib0330","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1093\/aje\/kwq300","article-title":"Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition","volume":"172","author":"Allen","year":"2010","journal-title":"Am. J. Epidemiol."},{"issue":"12","key":"10.1016\/j.canep.2015.08.003_bib0335","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s10552-011-9840-6","article-title":"Long-term use of continuous-combined estrogen-progestin hormone therapy and risk of endometrial cancer","volume":"22","author":"Phipps","year":"2011","journal-title":"Cancer Causes Control"},{"issue":"2","key":"10.1016\/j.canep.2015.08.003_bib0340","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/ijc.27623","article-title":"Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk?","volume":"132","author":"Trabert","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canep.2015.08.003_bib0345","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jsbmb.2013.05.001","article-title":"Menopausal hormone therapy and risk of endometrial cancer","volume":"142","author":"Brinton","year":"2014","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"3","key":"10.1016\/j.canep.2015.08.003_bib0350","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/cncr.23956","article-title":"Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin","volume":"115","author":"Pearce","year":"2009","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.canep.2015.08.003_bib0355","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s10552-011-9782-z","article-title":"Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition","volume":"22","author":"Tsilidis","year":"2011","journal-title":"Cancer Causes Control"},{"issue":"12","key":"10.1016\/j.canep.2015.08.003_bib0360","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1093\/aje\/kwr446","article-title":"Hormone therapy and different ovarian cancers: a national cohort study","volume":"175","author":"M\u00f8rch","year":"2012","journal-title":"Am. J. Epidemiol."},{"issue":"9980","key":"10.1016\/j.canep.2015.08.003_bib0365","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(14)61687-1","article-title":"Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies","volume":"385","author":"Beral","year":"2015","journal-title":"Lancet"},{"issue":"9574","key":"10.1016\/j.canep.2015.08.003_bib0370","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/S0140-6736(07)60534-0","article-title":"Ovarian cancer and hormone replacement therapy in the Million Women Study","volume":"369","author":"Beral","year":"2007","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.canep.2015.08.003_bib0375","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3109\/13697137.2015.1023615","article-title":"A Commentary on a recent update of the ovarian cancer risk attributable to menopausal hormone therapy","volume":"18","author":"Gompel","year":"2015","journal-title":"Climacteric"},{"issue":"5","key":"10.1016\/j.canep.2015.08.003_bib0380","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S0002-9343(99)00063-7","article-title":"Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis","volume":"106","author":"Grodstein","year":"1999","journal-title":"Am. J. Med."},{"issue":"5 Pt. 2","key":"10.1016\/j.canep.2015.08.003_bib0385","first-page":"880","article-title":"Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis","volume":"93","author":"Nanda","year":"1999","journal-title":"Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.canep.2015.08.003_bib0390","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3109\/13697137.2012.659450","article-title":"Colorectal cancer in women: hormone replacement therapy and chemoprevention","volume":"15","author":"Barnes","year":"2012","journal-title":"Climacteric"},{"issue":"2","key":"10.1016\/j.canep.2015.08.003_bib0395","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/ijc.26026","article-title":"The effect of estrogen vs. combined estrogen-progestogen therapy on the risk of colorectal cancer","volume":"130","author":"Lin","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"10","key":"10.1016\/j.canep.2015.08.003_bib0400","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1002\/ijc.26236","article-title":"Menopausal hormone therapy and risk of gastrointestinal cancer: nested case-control study within a prospective cohort, and meta-analysis","volume":"130","author":"Green","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.canep.2015.08.003_bib0405","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s10552-013-0201-5","article-title":"Meta-analyses of colorectal cancer risk factors","volume":"24","author":"Johnson","year":"2013","journal-title":"Cancer Causes Control"},{"issue":"4","key":"10.1016\/j.canep.2015.08.003_bib0410","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/cmt.6.4.285.292","article-title":"Meningioma and hormonal influences","volume":"6","author":"Wahab","year":"2003","journal-title":"Climacteric"},{"issue":"2","key":"10.1016\/j.canep.2015.08.003_bib0415","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1200\/JCO.2007.14.2133","article-title":"Is there an association between meningioma and hormone replacement therapy?","volume":"26","author":"Blitshteyn","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.canep.2015.08.003_bib0420","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/ijc.25184","article-title":"Hormone replacement therapy and incidence of central nervous system tumours in the Million Women Study","volume":"127","author":"Benson","year":"2010","journal-title":"Int. J. Cancer"},{"issue":"15","key":"10.1016\/j.canep.2015.08.003_bib0425","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1016\/j.ejca.2013.05.026","article-title":"Hormone replacement therapy increases the risk of cranial meningioma","volume":"49","author":"Andersen","year":"2013","journal-title":"Eur. J. Cancer"},{"issue":"8","key":"10.1016\/j.canep.2015.08.003_bib0430","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s10552-013-0228-7","article-title":"Hormone replacement therapy and risk of meningioma in women: a meta-analysis","volume":"24","author":"Fan","year":"2013","journal-title":"Cancer Causes Control"},{"issue":"1","key":"10.1016\/j.canep.2015.08.003_bib0435","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1158\/1055-9965.EPI-11-0834","article-title":"Sex hormones, hormonal interventions, and gastric cancer risk: a meta-analysis","volume":"21","author":"Camargo","year":"2012","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"9","key":"10.1016\/j.canep.2015.08.003_bib0440","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1002\/ijc.28869","article-title":"Hormone replacement therapy and oral contraceptives and risk of oesophageal adenocarcinoma: a systematic review and meta-analysis","volume":"135","author":"Lagergren","year":"2014","journal-title":"Int. J. Cancer"},{"issue":"8","key":"10.1016\/j.canep.2015.08.003_bib0445","doi-asserted-by":"crossref","first-page":"e71236","DOI":"10.1371\/journal.pone.0071236","article-title":"Hormone replacement therapy in females can decrease the risk of lung cancer: a meta-analysis","volume":"8","author":"Yao","year":"2013","journal-title":"PLoS One"},{"issue":"18","key":"10.1016\/j.canep.2015.08.003_bib0450","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/jnci\/djq285","article-title":"Lung cancer among postmenopausal women treated with estrogen alone in the women\u2019s health initiative randomized trial","volume":"102","author":"Chlebowski","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"issue":"9697","key":"10.1016\/j.canep.2015.08.003_bib0455","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0140-6736(09)61526-9","article-title":"Oestrogen plus progestin and lung cancer in postmenopausal women (Women\u2019s Health Initiative trial): a post-hoc analysis of a randomised controlled trial","volume":"374","author":"Chlebowski","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.canep.2015.08.003_bib0460","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.contraception.2012.11.021","article-title":"Prescription requirements and over-the-counter access to oral contraceptives: a global review","volume":"88","author":"Grindlay","year":"2013","journal-title":"Contraception"},{"key":"10.1016\/j.canep.2015.08.003_bib0465","series-title":"Guidelines for ATC Classification and DDD Assignment","author":"WHO Collaborating Centre for Drug Statistics Methodology","year":"2013"},{"issue":"6","key":"10.1016\/j.canep.2015.08.003_bib0470","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.amjmed.2009.01.016","article-title":"Helping women choose appropriate hormonal contraception: update on risks, benefits, and indications","volume":"122","author":"Spencer","year":"2009","journal-title":"Am. J. Med."},{"issue":"2","key":"10.1016\/j.canep.2015.08.003_bib0475","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/019262338901700214","article-title":"Guidelines and requirements for the evaluation of contraceptive steroids","volume":"17","author":"McKenzie","year":"1989","journal-title":"Toxicol. Pathol."},{"issue":"6","key":"10.1016\/j.canep.2015.08.003_bib0480","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/humupd\/dmq022","article-title":"Hormonal contraception and risk of cancer","volume":"16","author":"Cibula","year":"2010","journal-title":"Hum. Reprod. Update"},{"issue":"2","key":"10.1016\/j.canep.2015.08.003_bib0485","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1177\/0300985812450727","article-title":"History of chronic toxicity and animal carcinogenicity studies for pharmaceuticals","volume":"50","author":"Jacobs","year":"2013","journal-title":"Vet. Pathol."},{"issue":"9017","key":"10.1016\/j.canep.2015.08.003_bib0490","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0140-6736(96)90806-5","article-title":"Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies","volume":"347","year":"1996","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.canep.2015.08.003_bib0495","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.4065\/81.10.1290","article-title":"Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis","volume":"81","author":"Kahlenborn","year":"2006","journal-title":"Mayo Clin. Proc."},{"issue":"6","key":"10.1016\/j.canep.2015.08.003_bib0500","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3109\/13625187.2012.715357","article-title":"Oral contraceptive use and risk of breast cancer: a meta-analysis of prospective cohort studies","volume":"17","author":"Zhu","year":"2012","journal-title":"Eur. J. Contracept. Reprod. Health Care"},{"issue":"9599","key":"10.1016\/j.canep.2015.08.003_bib0505","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/S0140-6736(07)61684-5","article-title":"Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies","volume":"370","author":"Appleby","year":"2007","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.canep.2015.08.003_bib0510","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jhep.2007.03.015","article-title":"Oral contraception and the risk of hepatocellular carcinoma","volume":"47","author":"Maheshwari","year":"2007","journal-title":"J. Hepatol."},{"key":"10.1016\/j.canep.2015.08.003_bib0515","doi-asserted-by":"crossref","first-page":"f5298","DOI":"10.1136\/bmj.f5298","article-title":"Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis","volume":"347","author":"Stegeman","year":"2013","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.canep.2015.08.003_bib0520","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/AOG.0b013e318291c235","article-title":"Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis","volume":"122","author":"Havrilesky","year":"2013","journal-title":"Obstet. Gynecol."},{"issue":"4","key":"10.1016\/j.canep.2015.08.003_bib0525","doi-asserted-by":"crossref","first-page":"R263","DOI":"10.1677\/ERC-10-0076","article-title":"Hormonal contraception and risk of endometrial cancer: a systematic review","volume":"17","author":"Mueck","year":"2010","journal-title":"Endocr. Relat. Cancer"},{"issue":"1 Pt. 1","key":"10.1016\/j.canep.2015.08.003_bib0530","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0002-9378(95)90125-6","article-title":"Primary prevention of gynecologic cancers","volume":"172","author":"Grimes","year":"1995","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"9","key":"10.1016\/j.canep.2015.08.003_bib0535","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1093\/humrep\/12.9.1851","article-title":"Risk of endometrial cancer in relation to use of combined oral contraceptives. A practitioner\u2019s guide to meta-analysis","volume":"12","author":"Schlesselman","year":"1997","journal-title":"Hum. Reprod."},{"issue":"5","key":"10.1016\/j.canep.2015.08.003_bib0540","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1054\/bjoc.2000.1622","article-title":"Oral contraceptives and colorectal cancer risk: a meta-analysis","volume":"84","author":"Fernandez","year":"2001","journal-title":"Br. J. Cancer"},{"issue":"7","key":"10.1016\/j.canep.2015.08.003_bib0545","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/sj.bjc.6600196","article-title":"A pooled analysis of 10 case-control studies of melanoma and oral contraceptive use","volume":"86","author":"Karagas","year":"2002","journal-title":"Br. J. Cancer"},{"issue":"9364","key":"10.1016\/j.canep.2015.08.003_bib0550","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(03)12949-2","article-title":"Cervical cancer and use of hormonal contraceptives: a systematic review","volume":"361","author":"Smith","year":"2003","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.canep.2015.08.003_bib0555","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/humupd\/dmp017","article-title":"Oral contraceptives and colorectal cancer risk: a systematic review and meta-analysis","volume":"15","author":"Bosetti","year":"2009","journal-title":"Hum. Reprod. Update"},{"issue":"12","key":"10.1016\/j.canep.2015.08.003_bib0560","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/j.ejca.2010.04.018","article-title":"Oral contraceptive use and breast or ovarian cancer risk in BRCA1\/2 carriers: a meta-analysis","volume":"46","author":"Iodice","year":"2010","journal-title":"Eur. J. Cancer"},{"issue":"29","key":"10.1016\/j.canep.2015.08.003_bib0565","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.3748\/wjg.v16.i29.3603","article-title":"Non-viral causes of hepatocellular carcinoma","volume":"16","author":"Blonski","year":"2010","journal-title":"World J. Gastroenterol."},{"issue":"8","key":"10.1016\/j.canep.2015.08.003_bib0570","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1586\/era.11.38","article-title":"Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis","volume":"11","author":"Cibula","year":"2011","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"17","key":"10.1016\/j.canep.2015.08.003_bib0575","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1016\/j.ejca.2011.04.023","article-title":"Hormonal and reproductive factors in relation to melanoma in women: current review and meta-analysis","volume":"47","author":"Gandini","year":"2011","journal-title":"Eur. J. Cancer"},{"issue":"9","key":"10.1016\/j.canep.2015.08.003_bib0580","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1093\/annonc\/mds171","article-title":"Menstrual and reproductive factors, and hormonal contraception use: associations with non-Hodgkin lymphoma in a pooled analysis of InterLymph case-control studies","volume":"23","author":"Kane","year":"2012","journal-title":"Ann. Oncol."},{"issue":"33","key":"10.1016\/j.canep.2015.08.003_bib0585","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1200\/JCO.2013.48.9021","article-title":"Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis","volume":"31","author":"Moorman","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.canep.2015.08.003_bib0590","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1158\/1055-9965.EPI-13-0298","article-title":"Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review","volume":"22","author":"Gierisch","year":"2013","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"3","key":"10.1016\/j.canep.2015.08.003_bib0595","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.7314\/APJCP.2014.15.3.1205","article-title":"Association of oral contraceptives use and lung cancer risk among women: an updated meta-analysis based on cohort and case-control studies","volume":"15","author":"Wu","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"11","key":"10.1016\/j.canep.2015.08.003_bib0600","first-page":"3954","article-title":"Oral contraceptive use and kidney cancer risk among women: evidence from a meta-analysis","volume":"7","author":"Liu","year":"2014","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"5","key":"10.1016\/j.canep.2015.08.003_bib0605","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1470-2045(11)70030-4","article-title":"Preventive therapy for breast cancer: a consensus statement","volume":"12","author":"Cuzick","year":"2011","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.canep.2015.08.003_bib0610","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-158-8-201304160-00005","article-title":"Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force","volume":"158","author":"Nelson","year":"2013","journal-title":"Ann. Intern. Med."},{"issue":"11","key":"10.1016\/j.canep.2015.08.003_bib0615","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/jnci\/djp104","article-title":"Lifelong cancer incidence in 47,697 patients treated for childhood cancer in the Nordic countries","volume":"101","author":"Olsen","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.canep.2015.08.003_bib0620","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrclinonc.2013.41","article-title":"Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors","volume":"10","author":"Travis","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"30","key":"10.1016\/j.canep.2015.08.003_bib0625","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1200\/JCO.2012.41.8681","article-title":"Second malignant neoplasms: assessment and strategies for risk reduction","volume":"30","author":"Wood","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.canep.2015.08.003_bib0630","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1470-2045(08)70286-9","article-title":"A review of human carcinogens-Part A: pharmaceuticals","volume":"10","author":"Grosse","year":"2009","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.canep.2015.08.003_bib0635","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1053\/j.seminoncol.2008.04.012","article-title":"Therapy-related myeloid leukemia","volume":"35","author":"Godley","year":"2008","journal-title":"Semin. Oncol."},{"issue":"4","key":"10.1016\/j.canep.2015.08.003_bib0640","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/j.1476-5381.2010.01100.x","article-title":"Therapy-related myeloid neoplasms: pathobiology and clinical characteristics","volume":"162","author":"Sill","year":"2011","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.canep.2015.08.003_bib0645","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1023\/A:1018453104303","article-title":"Aromatic amines and cancer","volume":"8","author":"Vineis","year":"1997","journal-title":"Cancer Causes Control"},{"issue":"31","key":"10.1016\/j.canep.2015.08.003_bib0650","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1200\/JCO.2011.34.8268","article-title":"Second cancer risk after chemotherapy for Hodgkin\u2019s lymphoma: a collaborative British cohort study","volume":"29","author":"Swerdlow","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.canep.2015.08.003_bib0655","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrclinonc.2013.41","article-title":"Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors","volume":"10","author":"Travis","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.canep.2015.08.003_bib0660","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1172\/JCI200318384","article-title":"Azathioprine old drug, new actions","volume":"111","author":"Maltzman","year":"2003","journal-title":"J. Clin. Invest."},{"issue":"Suppl. (2)","key":"10.1016\/j.canep.2015.08.003_bib0665","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/vr.102484","article-title":"Ciclosporin 10 years on: indications and efficacy","volume":"174","author":"Forsythe","year":"2014","journal-title":"Vet. Rec."},{"issue":"9","key":"10.1016\/j.canep.2015.08.003_bib0670","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nrneph.2010.102","article-title":"Malignancy after renal transplantation: the role of immunosuppression","volume":"6","author":"Rama","year":"2010","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.canep.2015.08.003_bib0675","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3389\/fimmu.2014.00197","article-title":"Does the immune system naturally protect against cancer?","volume":"5","author":"Corthay","year":"2014","journal-title":"Front. Immunol."},{"issue":"17","key":"10.1016\/j.canep.2015.08.003_bib0680","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMra022137","article-title":"Skin cancers after organ transplantation","volume":"348","author":"Euvrard","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.canep.2015.08.003_bib0685","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2165\/00003495-200767080-00006","article-title":"Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review","volume":"67","author":"Gutierrez-Dalmau","year":"2007","journal-title":"Drugs"},{"issue":"17","key":"10.1016\/j.canep.2015.08.003_bib0690","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2011.1592","article-title":"Spectrum of cancer risk among US solid organ transplant recipients","volume":"306","author":"Engels","year":"2011","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.canep.2015.08.003_bib0695","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/em.21732","article-title":"Evidence of exposure to aristolochic acid in patients with urothelial cancer from a Balkan endemic nephropathy region of Romania","volume":"53","author":"Schmeiser","year":"2012","journal-title":"Environ. Mol. Mutagen"},{"issue":"21","key":"10.1016\/j.canep.2015.08.003_bib0700","doi-asserted-by":"crossref","first-page":"8241","DOI":"10.1073\/pnas.1119920109","article-title":"Aristolochic acid-associated urothelial cancer in Taiwan","volume":"109","author":"Chen","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.canep.2015.08.003_bib0705","first-page":"141","article-title":"Chemical and molecular basis of the carcinogenicity of Aristolochia plants","volume":"12","author":"Schmeiser","year":"2009","journal-title":"Curr. Opin. Drug Discov. Dev."},{"issue":"1","key":"10.1016\/j.canep.2015.08.003_bib0710","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.mrrev.2013.02.003","article-title":"Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid","volume":"753","author":"Hollstein","year":"2013","journal-title":"Mutat. Res."},{"issue":"1","key":"10.1016\/j.canep.2015.08.003_bib0715","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(12)70596-X","article-title":"Aristolochia the malignant truth","volume":"14","author":"Krell","year":"2013","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.canep.2015.08.003_bib0720","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2165\/00003495-199856040-00015","article-title":"5-Methoxypsoralen. A review of its effects in psoriasis and vitiligo","volume":"56","author":"McNeely","year":"1998","journal-title":"Drugs"},{"issue":"Suppl. (3)","key":"10.1016\/j.canep.2015.08.003_bib0725","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1468-3083.2012.04520.x","article-title":"Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review","volume":"26","author":"Archier","year":"2012","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"16","key":"10.1016\/j.canep.2015.08.003_bib0730","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1001\/archinternmed.2012.2754","article-title":"Antihypertensive drugs and lip cancer in non-Hispanic whites","volume":"172","author":"Friedman","year":"2012","journal-title":"Arch. Intern. Med."},{"issue":"6","key":"10.1016\/j.canep.2015.08.003_bib0735","first-page":"1332","article-title":"Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids)","volume":"35","author":"Sporn","year":"1976","journal-title":"Fed. Proc."},{"issue":"1","key":"10.1016\/j.canep.2015.08.003_bib0740","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1373\/clinchem.2012.185389","article-title":"Cancer chemoprevention: successes and failures","volume":"59","author":"Patterson","year":"2013","journal-title":"Clin. Chem."},{"key":"10.1016\/j.canep.2015.08.003_bib0745","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jsbmb.2013.12.011","article-title":"Use of SERMs for treatment in postmenopausal women","volume":"142C","author":"Pinkerton","year":"2014","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"5","key":"10.1016\/j.canep.2015.08.003_bib0750","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ctrv.2012.07.006","article-title":"The development of endocrine therapy for women with breast cancer","volume":"39","author":"Sainsbury","year":"2013","journal-title":"Cancer Treat. Rev."},{"issue":"23","key":"10.1016\/j.canep.2015.08.003_bib0755","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1200\/JCO.2013.49.3122","article-title":"Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline","volume":"31","author":"Visvanathan","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"9880","key":"10.1016\/j.canep.2015.08.003_bib0760","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/S0140-6736(13)60140-3","article-title":"Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data","volume":"381","author":"Cuzick","year":"2013","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.canep.2015.08.003_bib0765","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","article-title":"Exemestane for breast-cancer prevention in postmenopausal women","volume":"364","author":"Goss","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"9922","key":"10.1016\/j.canep.2015.08.003_bib0770","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(13)62292-8","article-title":"Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial","volume":"383","author":"Cuzick","year":"2014","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.canep.2015.08.003_bib0775","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1470-2045(09)70035-X","article-title":"Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement","volume":"10","author":"Cuzick","year":"2009","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.canep.2015.08.003_bib0780","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1158\/1940-6207.CAPR-11-0391","article-title":"Aspirin in the chemoprevention of colorectal neoplasia: an overview","volume":"5","author":"Chan","year":"2012","journal-title":"Cancer Prev. Res. (Phila)"},{"issue":"5","key":"10.1016\/j.canep.2015.08.003_bib0785","doi-asserted-by":"crossref","first-page":"347","DOI":"10.7326\/M15-0039","article-title":"Low-dose aspirin or nonsteroidal anti-inflammatory drug use and colorectal cancer risk: A population-based, case-control study","volume":"163","author":"Friis","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.canep.2015.08.003_bib0790","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/annonc\/mdu225","article-title":"Estimates of benefits and harms of prophylactic use of aspirin in the general population","volume":"1","author":"Cuzick","year":"2015","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.canep.2015.08.003_bib0795","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-159-2-201307160-00002","article-title":"Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial","volume":"159","author":"Cook","year":"2013","journal-title":"Ann. Intern. Med."},{"issue":"9754","key":"10.1016\/j.canep.2015.08.003_bib0800","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","article-title":"Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials","volume":"376","author":"Rothwell","year":"2010","journal-title":"Lancet"},{"issue":"9826","key":"10.1016\/j.canep.2015.08.003_bib0805","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S0140-6736(11)61720-0","article-title":"Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials","volume":"379","author":"Rothwell","year":"2012","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.canep.2015.08.003_bib0810","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1053\/j.gastro.2006.08.079","article-title":"A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas","volume":"131","author":"Baron","year":"2006","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.canep.2015.08.003_bib0815","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1056\/NEJMoa061355","article-title":"Celecoxib for the prevention of sporadic colorectal adenomas","volume":"355","author":"Bertagnolli","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.canep.2015.08.003_bib0820","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa061652","article-title":"Celecoxib for the prevention of colorectal adenomatous polyps","volume":"355","author":"Arber","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.canep.2015.08.003_bib0825","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jnci\/djn485","article-title":"Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials","volume":"101","author":"Cole","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"issue":"11","key":"10.1016\/j.canep.2015.08.003_bib0830","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1136\/gutjnl-2013-305827","article-title":"The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial","volume":"63","author":"Ishikawa","year":"2014","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.canep.2015.08.003_bib0835","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1002\/bjs.1800801244","article-title":"Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis","volume":"80","author":"Nugent","year":"1993","journal-title":"Br. J. Surg."},{"issue":"5","key":"10.1016\/j.canep.2015.08.003_bib0840","first-page":"655","article-title":"Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial","volume":"4","author":"Burn","year":"2011","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.canep.2015.08.003_bib0845","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s10620-009-0915-0","article-title":"Aspirin use and the risk of gastric cancer: a meta-analysis","volume":"55","author":"Yang","year":"2010","journal-title":"Dig. Dis. Sci."},{"issue":"8","key":"10.1016\/j.canep.2015.08.003_bib0850","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1442-2050.2011.01198.x","article-title":"Meta-analysis non-steroidal anti-inflammatory drug use and the risk of esophageal squamous cell carcinoma","volume":"24","author":"Sun","year":"2011","journal-title":"Dis. Esophagus"},{"issue":"7","key":"10.1016\/j.canep.2015.08.003_bib0855","doi-asserted-by":"crossref","first-page":"e71522","DOI":"10.1371\/journal.pone.0071522","article-title":"Frequency-risk and duration-risk relationships between aspirin use and gastric cancer: a systematic review and meta-analysis","volume":"8","author":"Ye","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.canep.2015.08.003_bib0860","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/1751-2980.12047","article-title":"Role of aspirin in chemoprevention of esophageal adenocarcinoma: a meta-analysis","volume":"14","author":"Sivarasan","year":"2013","journal-title":"J. Dig. Dis."},{"issue":"20","key":"10.1016\/j.canep.2015.08.003_bib0865","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/jnci\/djn324","article-title":"Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis","volume":"100","author":"Takkouche","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.canep.2015.08.003_bib0870","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10549-008-0228-6","article-title":"Association between NSAIDs use and breast cancer risk: a systematic review and meta-analysis","volume":"117","author":"Zhao","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.canep.2015.08.003_bib0875","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s10549-011-1747-0","article-title":"Aspirin use and breast cancer risk: a meta-analysis","volume":"131","author":"Luo","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"issue":"11","key":"10.1016\/j.canep.2015.08.003_bib0880","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1093\/annonc\/mdq779","article-title":"Aspirin use and risk for lung cancer: a meta-analysis","volume":"22","author":"Oh","year":"2011","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.canep.2015.08.003_bib0885","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cllc.2011.06.009","article-title":"Meta-analysis on the association between nonsteroidal anti-inflammatory drug use and lung cancer risk","volume":"13","author":"Xu","year":"2012","journal-title":"Clin. Lung Cancer"},{"issue":"5","key":"10.1016\/j.canep.2015.08.003_bib0890","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1002\/ijc.27717","article-title":"Aspirin, nonsteroidal anti-inflammatory drugs, paracetamol and risk of endometrial cancer: a case-control study, systematic review and meta-analysis","volume":"132","author":"Neill","year":"2013","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.canep.2015.08.003_bib0895","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/EDE.0b013e3182456ad3","article-title":"Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, or acetaminophen and risk of ovarian cancer","volume":"23","author":"Lo-Ciganic","year":"2012","journal-title":"Epidemiology"},{"issue":"3","key":"10.1016\/j.canep.2015.08.003_bib0900","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/aogs.12069","article-title":"Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: systematic review and meta-analysis of observational studies","volume":"92","author":"Baandrup","year":"2013","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"10.1016\/j.canep.2015.08.003_bib0905","doi-asserted-by":"crossref","DOI":"10.1007\/s11255-014-0703-4","article-title":"Aspirin use and the risk of prostate cancer: a meta-analysis of 24 epidemiologic studies","author":"Huang","year":"2014","journal-title":"Int. Urol. Nephrol."},{"key":"10.1016\/j.canep.2015.08.003_bib0910","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1741-7015-12-55","article-title":"Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: a systematic review and meta-analysis","volume":"12","author":"Liu","year":"2014","journal-title":"BMC Med."},{"issue":"11","key":"10.1016\/j.canep.2015.08.003_bib0915","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1158\/1940-6207.CAPR-11-0166","article-title":"Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention","volume":"4","author":"Fischer","year":"2011","journal-title":"Cancer Prev. Res. (Phila)"},{"issue":"5","key":"10.1016\/j.canep.2015.08.003_bib0920","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrclinonc.2011.199","article-title":"The role of aspirin in cancer prevention","volume":"9","author":"Thun","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.canep.2015.08.003_bib0925","doi-asserted-by":"crossref","first-page":"17972","DOI":"10.3390\/ijms140917972","article-title":"Mechanisms of action of non-steroidal anti-inflammatory drugs (NSAIDs) and mesalazine in the chemoprevention of colorectal cancer","volume":"14","author":"Stolfi","year":"2013","journal-title":"Int. J. Mol. Sci."},{"issue":"9894","key":"10.1016\/j.canep.2015.08.003_bib0930","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","article-title":"Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials","volume":"382","author":"Bhala","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.canep.2015.08.003_bib0935","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/pds.3437","article-title":"Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies","volume":"22","author":"Varas-Lorenzo","year":"2013","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"6","key":"10.1016\/j.canep.2015.08.003_bib0940","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s11912-013-0351-3","article-title":"Role of aspirin in cancer prevention","volume":"15","author":"Thorat","year":"2013","journal-title":"Curr. Oncol. Rep."},{"issue":"6","key":"10.1016\/j.canep.2015.08.003_bib0945","doi-asserted-by":"crossref","first-page":"379","DOI":"10.7326\/0003-4819-150-6-200903170-00006","article-title":"Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding","volume":"150","author":"Steinhubl","year":"2009","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.canep.2015.08.003_bib0950","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1124\/pr.111.004994","article-title":"Pharmacological actions of statins: a critical appraisal in the management of cancer","volume":"64","author":"Gazzerro","year":"2012","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"10.1016\/j.canep.2015.08.003_bib0955","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2012.04.011","article-title":"Statins and cancer: current and future prospects","volume":"324","author":"Osmak","year":"2012","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.canep.2015.08.003_bib0960","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cgh.2012.08.037","article-title":"Statins and colorectal cancer","volume":"11","author":"Lochhead","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"10","key":"10.1016\/j.canep.2015.08.003_bib0965","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.dld.2013.02.002","article-title":"Statins perspectives in cancer therapeutics","volume":"45","author":"Corcos","year":"2013","journal-title":"Dig. Liver Dis."},{"issue":"4","key":"10.1016\/j.canep.2015.08.003_bib0970","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1517\/14740331003662620","article-title":"Statin use and cancer risk: a comprehensive review","volume":"9","author":"Boudreau","year":"2010","journal-title":"Expert Opin. Drug Saf."},{"issue":"4","key":"10.1016\/j.canep.2015.08.003_bib0975","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/ijc.23550","article-title":"Statin use and the risk of prostate cancer: a metaanalysis of 6 randomized clinical trials and 13 observational studies","volume":"123","author":"Bonovas","year":"2008","journal-title":"Int. J. Cancer"},{"issue":"10","key":"10.1016\/j.canep.2015.08.003_bib0980","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1007\/s00228-013-1547-z","article-title":"Statins are associated with reduced risk of gastric cancer: a meta-analysis","volume":"69","author":"Wu","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"7","key":"10.1016\/j.canep.2015.08.003_bib0985","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1093\/annonc\/mdt150","article-title":"Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis","volume":"24","author":"Singh","year":"2013","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.canep.2015.08.003_bib0990","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2012.10.005","article-title":"Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis","volume":"144","author":"Singh","year":"2013","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.canep.2015.08.003_bib0995","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.cgh.2012.12.036","article-title":"Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysis","volume":"11","author":"Singh","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"32","key":"10.1016\/j.canep.2015.08.003_bib1000","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1200\/JCO.2013.50.9208","article-title":"Statins and reduced risk of hepatocellular carcinoma in patients with hepatitis C virus infection: further evidence is warranted","volume":"31","author":"Bonovas","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.canep.2015.08.003_bib1005","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/CEJ.0b013e328358761a","article-title":"Statins and primary liver cancer: a meta-analysis of observational studies","volume":"22","author":"Pradelli","year":"2013","journal-title":"Eur. J. Cancer Prev."},{"issue":"7","key":"10.1016\/j.canep.2015.08.003_bib1010","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.3748\/wjg.v20.i7.1858","article-title":"Statins and the risk of colorectal cancer: an updated systematic review and meta-analysis of 40 studies","volume":"20","author":"Lytras","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.canep.2015.08.003_bib1015","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10552-013-0326-6","article-title":"Association between statin use and colorectal cancer risk: a meta-analysis of 42 studies","volume":"25","author":"Liu","year":"2014","journal-title":"Cancer Causes Control"},{"issue":"3","key":"10.1016\/j.canep.2015.08.003_bib1020","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ygyno.2014.04.007","article-title":"Effect of statin on risk of gynecologic cancers: a meta-analysis of observational studies and randomized controlled trials","volume":"133","author":"Liu","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.canep.2015.08.003_bib1025","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.clinre.2013.09.007","article-title":"Statin and aspirin for prevention of hepatocellular carcinoma: what are the levels of evidence?","volume":"38","author":"Carrat","year":"2014","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"issue":"10","key":"10.1016\/j.canep.2015.08.003_bib1030","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.2337\/dc11-0512","article-title":"Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis","volume":"34","author":"Zhang","year":"2011","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.canep.2015.08.003_bib1035","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1007\/s00125-012-2653-7","article-title":"Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials","volume":"55","author":"Stevens","year":"2012","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.canep.2015.08.003_bib1040","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1007\/s12032-011-9846-7","article-title":"Metformin and cancer: new applications for an old drug","volume":"29","author":"Kourelis","year":"2012","journal-title":"Med. Oncol."},{"issue":"3","key":"10.1016\/j.canep.2015.08.003_bib1045","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s10549-012-2170-x","article-title":"Metformin and breast cancer risk: a meta-analysis and critical literature review","volume":"135","author":"Col","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"issue":"7","key":"10.1016\/j.canep.2015.08.003_bib1050","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1210\/jc.2012-1267","article-title":"Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"97","author":"Zhang","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.canep.2015.08.003_bib1055","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.metabol.2013.01.014","article-title":"Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies","volume":"62","author":"Thakkar","year":"2013","journal-title":"Metabolism"},{"issue":"1\u20133","key":"10.1016\/j.canep.2015.08.003_bib1060","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejphar.2013.02.038","article-title":"Metformin and cancer","volume":"705","author":"Rizos","year":"2013","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.canep.2015.08.003_bib1065","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.canep.2012.12.009","article-title":"Association of metformin use with cancer incidence and mortality: a meta-analysis","volume":"37","author":"Zhang","year":"2013","journal-title":"Cancer Epidemiol."},{"issue":"1","key":"10.1016\/j.canep.2015.08.003_bib1070","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/aje\/kwu124","article-title":"Reduced risk of lung cancer with metformin therapy in diabetic patients: a systematic review and meta-analysis","volume":"180","author":"Zhang","year":"2014","journal-title":"Am. J. Epidemiol."},{"issue":"6","key":"10.1016\/j.canep.2015.08.003_bib1075","first-page":"57","article-title":"Metformin in cancer prevention and therapy","volume":"2","author":"Kasznicki","year":"2014","journal-title":"Ann. Transl. Med."},{"issue":"9","key":"10.1016\/j.canep.2015.08.003_bib1080","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1158\/1940-6207.CAPR-13-0424","article-title":"Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders","volume":"7","author":"Gandini","year":"2014","journal-title":"Cancer Prev. Res. (Phila)"},{"issue":"7","key":"10.1016\/j.canep.2015.08.003_bib1085","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s10552-012-9971-4","article-title":"Diabetes and cancer II: role of diabetes medications and influence of shared risk factors","volume":"23","author":"Onitilo","year":"2012","journal-title":"Cancer Causes Control"},{"issue":"11","key":"10.1016\/j.canep.2015.08.003_bib1090","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1592\/phco.30.11.1159","article-title":"Diabetes mellitus and increased risk of cancer: focus on metformin and the insulin analogs","volume":"30","author":"McFarland","year":"2010","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.canep.2015.08.003_bib1095","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa030660","article-title":"The influence of finasteride on the development of prostate cancer","volume":"349","author":"Thompson","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.canep.2015.08.003_bib1100","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1056\/NEJMoa0908127","article-title":"Effect of dutasteride on the risk of prostate cancer","volume":"362","author":"Andriole","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.canep.2015.08.003_bib1105","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.urology.2012.01.024","article-title":"Role of 5alpha-reductase inhibitors in prostate cancer prevention and treatment","volume":"79","author":"Azzouni","year":"2012","journal-title":"Urology"},{"issue":"7","key":"10.1016\/j.canep.2015.08.003_bib1110","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1215932","article-title":"Long-term survival of participants in the prostate cancer prevention trial","volume":"369","author":"Thompson","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.canep.2015.08.003_bib1115","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00345-011-0822-9","article-title":"Chemoprevention of prostate cancer: an updated view","volume":"30","author":"Klein","year":"2012","journal-title":"World J. Urol."},{"issue":"3","key":"10.1016\/j.canep.2015.08.003_bib1120","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1053\/j.seminoncol.2013.04.003","article-title":"Prostate cancer chemoprevention","volume":"40","author":"Sandhu","year":"2013","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.canep.2015.08.003_bib1125","article-title":"IARC monographs on the evaluation of carcinogenic risks to humans","volume":"vol. 100D","author":"International Agency for Research on Cancer","year":"2012"},{"key":"10.1016\/j.canep.2015.08.003_bib1130","series-title":"Report to the General Assembly, vol. 1, with Scientific Annexes A and B","article-title":"UNSCEAR 2006 Report: Sources and Effects of Ionizing Radiation","author":"United Nations Scientific Committee on the Effects of Atomic Radiation","year":"2008"},{"key":"10.1016\/j.canep.2015.08.003_bib1135","series-title":"ICRP Publication 103: Recommendations of the International Commission for Radiation Protection","author":"International Commission on Radiological Protection (ICRP)","year":"2012"},{"key":"10.1016\/j.canep.2015.08.003_bib1140","series-title":"Report to the General Assembly, vol. 1: Effects","article-title":"UNSCEAR 2000 Report: Sources and Effects of Ionizing Radiation","author":"United Nations Scientific Committee on the Effects of Atomic Radiation","year":"2000"},{"key":"10.1016\/j.canep.2015.08.003_bib1145","series-title":"Report to the General Assembly with scientific annexes A and B","article-title":"UNSCEAR 2008 Report: Sources and Effects of Ionizing Radiation","author":"United Nations Scientific Committee on the Effects of Atomic Radiation","year":"2010"},{"issue":"2","key":"10.1016\/j.canep.2015.08.003_bib1150","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<398::AID-CNCR22>3.0.CO;2-V","article-title":"Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery","volume":"88","author":"Brenner","year":"2000","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.canep.2015.08.003_bib1155","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00004032-200307000-00011","article-title":"Cancer risks from medical radiation","volume":"85","author":"Ron","year":"2003","journal-title":"Health Phys."},{"issue":"5086","key":"10.1016\/j.canep.2015.08.003_bib1160","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1136\/bmj.1.5086.1495","article-title":"A survey of childhood malignancies","volume":"1","author":"Stewart","year":"1958","journal-title":"Br. Med. J."},{"issue":"2","key":"10.1016\/j.canep.2015.08.003_bib1165","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/rpd\/ncn272","article-title":"Childhood leukaemia following medical diagnostic exposure to ionizing radiation in utero or after birth","volume":"132","author":"Wakeford","year":"2008","journal-title":"Radiat. Prot. Dosim."},{"issue":"2","key":"10.1016\/j.canep.2015.08.003_bib1170","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2307\/3577890","article-title":"Frequent chest X-ray fluoroscopy and breast cancer incidence among tuberculosis patients in Massachusetts","volume":"125","author":"Boice","year":"1991","journal-title":"Radiat. Res."},{"issue":"6","key":"10.1016\/j.canep.2015.08.003_bib1175","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2307\/3579360","article-title":"Breast cancer mortality between 1950 and 1987 after exposure to fractionated moderate-dose-rate ionizing radiation in the Canadian fluoroscopy cohort study and a comparison with breast cancer mortality in the atomic bomb survivors study","volume":"145","author":"Howe","year":"1996","journal-title":"Radiat. Res."},{"issue":"16","key":"10.1016\/j.canep.2015.08.003_bib1180","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1097\/00007632-200008150-00009","article-title":"Breast cancer mortality after diagnostic radiography: findings from the U.S. Scoliosis Cohort Study","volume":"25","author":"Doody","year":"2000","journal-title":"Spine (Phila Pa 1976)"},{"issue":"9406","key":"10.1016\/j.canep.2015.08.003_bib1185","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(04)15433-0","article-title":"Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries","volume":"363","author":"Berrington de Gonz\u00e1lez","year":"2004","journal-title":"Lancet"},{"issue":"9840","key":"10.1016\/j.canep.2015.08.003_bib1190","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(12)60815-0","article-title":"Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study","volume":"380","author":"Pearce","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.canep.2015.08.003_bib1195","doi-asserted-by":"crossref","first-page":"f2360","DOI":"10.1136\/bmj.f2360","article-title":"Cancer risk in 680,000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians","volume":"346","author":"Mathews","year":"2013","journal-title":"BMJ"}],"container-title":["Cancer Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782115001678?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782115001678?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T22:29:51Z","timestamp":1589581791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877782115001678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":239,"alternative-id":["S1877782115001678"],"URL":"https:\/\/doi.org\/10.1016\/j.canep.2015.08.003","relation":{},"ISSN":["1877-7821"],"issn-type":[{"value":"1877-7821","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"European Code against Cancer 4th Edition: Medical exposures, including hormone therapy, and cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canep.2015.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}